Aardvark Therapeutics, Inc. Common Stock AARD

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

• GlobeNewswire Inc. 5 oct

  AARDVARK THERAPEUTICS (NASDAQ: AARD) SECURITIES CLASS ACTION: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Investors to Secure Counsel Before Important October 13 Deadline

  Rosen Law Firm announces a securities class action lawsuit against Aardvark Therapeutics, with an October 13, 2026 deadline for investors to serve as lead plaintiff. The lawsuit alleges that defendants made materially false and misleading statements regarding the safety and prospects of their drug candidate ARD-101, causing investor damages when the true details emerged.

  

• GlobeNewswire Inc. 2 oct

  AARDVARK DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action – AARD

  Rosen Law Firm has announced multiple securities class action lawsuits against Aardvark Therapeutics, FuelCell Energy, and XTI Aerospace. The primary case involves Aardvark Therapeutics, where investors claim the company made materially false statements about the safety and prospects of its ARD-101 drug candidate in its IPO registration statement and throughout the class period. Investors have until October 13, 2026 to become lead plaintiffs in the Aardvark case.

  

• GlobeNewswire Inc. 2 oct

  Bronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

  A class action lawsuit has been filed against Aardvark Therapeutics, Inc. alleging securities fraud related to its February 2025 IPO and subsequent period through May 2026. The complaint claims the company made materially false and misleading statements about the safety and prospects of its drug candidate ARD-101, and that offering documents were negligently prepared. Investors who purchased shares during the class period are encouraged to join the lawsuit.

  

• GlobeNewswire Inc. 28 sept

  AARDVARK DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AARD

  Rosen Law Firm is reminding investors in Aardvark Therapeutics, Inc. (AARD) of an October 13, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Aardvark made materially false and misleading statements regarding the safety and prospects of its drug ARD-101, causing investor damages when the truth entered the market. The firm is also investigating claims related to Hyliion Holdings Corp. (HYLN) and FLOW cryptocurrency.

  

• GlobeNewswire Inc. 25 sept

  Bronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

  A class action lawsuit has been filed against Aardvark Therapeutics, Inc. alleging that offering documents contained false statements and that the company made materially misleading statements about the safety and prospects of its drug ARD-101. The lawsuit covers investors who purchased securities during the IPO on February 13, 2025, and through May 14, 2026. The lead plaintiff deadline is October 13, 2026.